Drugmakers Betting Big On Gene Therapy By Investing Combined $2B Into Manufacturing Pricey Treatments

And Pfizer and Novartis are leading the pack. The risks involved with drugmakers building their own manufacturing plants are big but so are the potential rewards. In other pharmaceutical news: a high-stakes bet on heart drugs, an invite-only club for biotech CEOs, President Donald Trump's importation plan, and more.

from Kaiser Health News https://ift.tt/33HnnmX